Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in HR-defective Esophageal/Gastric Cancer
NCT03840967Phase 2Terminated
- Start
- Jul 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib in esophageal adenocarcinoma (EAC), gastric adenocarcinoma. Started Jul 2019; status: terminated.
02
Drugs
niraparib
03
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT03840967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03840967.